143 related articles for article (PubMed ID: 37762490)
1. Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients.
Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Valencia H; Fong Y; Woo Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762490
[TBL] [Abstract][Full Text] [Related]
2. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.
Yang A; Zhang Z; Chaurasiya S; Park AK; Jung A; Lu J; Kim SI; Priceman S; Fong Y; Woo Y
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019471
[TBL] [Abstract][Full Text] [Related]
3. Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer.
Woo Y; Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Von Hoff D; Fong Y
J Am Coll Surg; 2020 Apr; 230(4):709-717. PubMed ID: 32032721
[TBL] [Abstract][Full Text] [Related]
4. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy.
Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Yuan YC; Liu Z; Han H; Von Hoff D; Fong Y; Woo Y
Cancer Gene Ther; 2022 Jun; 29(6):722-733. PubMed ID: 34108669
[TBL] [Abstract][Full Text] [Related]
5. PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1.
Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Olafsen T; Warner SG; Fong Y; Woo Y
Mol Ther Oncolytics; 2022 Mar; 24():331-339. PubMed ID: 35118191
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer.
Chaurasiya S; Yang A; Zhang Z; Lu J; Valencia H; Kim SI; Woo Y; Warner SG; Olafsen T; Zhao Y; Wu X; Fein S; Cheng L; Cheng M; Ede N; Fong Y
Mol Ther Methods Clin Dev; 2022 Mar; 24():102-116. PubMed ID: 35024377
[TBL] [Abstract][Full Text] [Related]
8. An oncolytic poxvirus encoding hNIS, shows anti-tumor efficacy and allows tumor imaging in a liver cancer model.
Chaurasiya S; Valencia H; Zhang Z; Kim SI; Yang A; Lu J; Woo Y; Warner SG; Ede NJ; Fong Y
Mol Cancer Ther; 2023 May; 22(7):882-90. PubMed ID: 37196156
[TBL] [Abstract][Full Text] [Related]
9. A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression.
Warner SG; Kim SI; Chaurasiya S; O'Leary MP; Lu J; Sivanandam V; Woo Y; Chen NG; Fong Y
Mol Ther Oncolytics; 2019 Jun; 13():82-92. PubMed ID: 31061881
[TBL] [Abstract][Full Text] [Related]
10. CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.
Yuan Y; Egelston C; Colunga Flores O; Chaurasiya S; Lin D; Chang H; Chong LMO; Seiz A; Shah M; Meisen WH; Tang A; Martinez N; Pickett W; Murga M; Yost SE; Stewart D; Zhang J; Ede N; Modi B; Kessler J; Rand J; Fong Y
Ther Adv Med Oncol; 2023; 15():17588359231210675. PubMed ID: 38028143
[TBL] [Abstract][Full Text] [Related]
11. An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model.
Chaurasiya S; Valencia H; Zhang Z; Kim SI; Yang A; Lu J; Woo Y; Warner SG; Ede NJ; Fong Y
Mol Cancer Ther; 2023 Jun; ():OF1-OF9. PubMed ID: 37294888
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
Zhang J; Guo Y; Fang H; Guo X; Zhao L
Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
[TBL] [Abstract][Full Text] [Related]
13. A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models.
Chaurasiya S; Chen NG; Lu J; Martin N; Shen Y; Kim SI; Warner SG; Woo Y; Fong Y
Cancer Gene Ther; 2020 Apr; 27(3-4):125-135. PubMed ID: 31209267
[TBL] [Abstract][Full Text] [Related]
14. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
15. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity.
Kim SI; Park AK; Chaurasiya S; Kang S; Lu J; Yang A; Sivanandam V; Zhang Z; Woo Y; Priceman SJ; Fong Y; Warner SG
Mol Cancer Ther; 2021 Jan; 20(1):173-182. PubMed ID: 33262221
[TBL] [Abstract][Full Text] [Related]
17. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Nguyen HM; Bommareddy PK; Silk AW; Saha D
Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases.
Yang A; Zhang Z; Chaurasiya S; Park AK; Lu J; Kim SI; Valencia H; Fong Y; Woo Y
Mol Ther Oncolytics; 2023 Dec; 31():100734. PubMed ID: 37915757
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic vaccinia virus acts synergistically with anti-PD-L1 antibody to enhance the killing of colon cancer cells by CD8
Wu R; Tong S; Yin J; Zhu Z; Mao Z; Xu L
Pathol Res Pract; 2023 Jul; 247():154535. PubMed ID: 37257241
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
